Oh, I'm on record for believing it would be well received; regardless that I may have been one who wanted to see more variables!
There's too many shorts to have a squeeze without outstanding trial or efficacy news. We need a catalyst of epic proportion to get the shorts to cover as a group. However, optimistic momentum continues to drive the price up. If you view it as a dug of war, with the shorts on one side and the longs on the other, the positive news (Woodford, Forbes, CUA data, Direct preliminary findings) they shared can be just as effective over time. Slowly but surely the longs are pulling the rope over the Fuerstein-Ratain Rule line, and the shorts have been losing their grip and are getting rope burned. Once the share price moves over resistances, it will be from that point the shorts have to readjust their grip to pull from. It makes it that much harder to pull back to zero as it moves up. But new shorts and longs will come into the equation at various points, so the long grip will lose players over time too. Me, for instance, I'm waiting for immune data to come in so I'm mostly trying options now (holding shares too). But, I do think some of the long-standing shorts will want out too, as it's been costly to continue to see losses. That's why I think once this gets over the F-R rule line, many more shorts will leave. And it will also bring additional longs to the equation. That will be a momentous move. :)
News 
Market Data 
Discover 
AI
